JAK1 and rheumatoid arthritis: There are currently 3 JAK inhibitors (JAKi), with differing JAK specificity, FDA-approved for the treatment of moderate-to-severe RA: tofacitinib (JAK1 >3), baricitinib (JAK 1 >2), and upadacitinib (selective JAK1).7